We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Pharmaceutical groups to part ways with longstanding executives
Pharma group seeks compensation from Covid vaccine maker for alleged IP infringements
New mRNA technology could make jabs better-matched to different annual strains and improve efficacy
German biotech had suffered disappointing results after initial excitement
UK pharma group has teamed up with South Korea’s SK Bioscience on jab that uses its adjuvant technology
Results of animal study show success in tackling several coronavirus variants
The mRNA pioneer was beaten by Moderna and BioNTech but is plotting a comeback
German drugmaker believes jab could still be used for some age groups or as booster
German biotech group’s shares plunge after interim results show jab only 47% effective
Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic
German company aims to produce up to 300m doses this year and 1bn in 2022
A transatlantic tug of love and a CEO brain haemorrhage afflicted the Bill Gates-backed biotech
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
Cynthia Carroll joins Glencore board, Bezos to step aside
€150m deal aims to have a vaccine ready for use in 2022
Collaboration will help German group deliver several hundred million doses after lagging behind competitors
German biotech group plans to test shot on 35,000 participants across Europe and Latin America
Democrats call postal chief to testify in US mail-in voting row
Pharma group plans to make mRNA-based inoculation in Germany and ship it worldwide
Shares in CureVac more than triple in New York, a day after CanSino also rises strongly
Deal increases UK drugmaker’s exposure to potential coronavirus vaccines
It is dispiriting to see countries squabbling over vaccine companies instead of finding a global solution
Investment of €300m to secure German drug company and potential treatment from foreign interest
Proponents say vaccines made of RNA and DNA will prove safer and cheaper
International Edition
